Hyperpolarized 13C Pyruvate

Phase 2Small molecule

Hyperpolarized 13C Pyruvate is one of 386 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

385

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerTerminated

Pancreatic CancerActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

ImagingRecruiting

ImmunotherapyNot yet recruiting

Neuroendocrine TumorsRecruiting

GliomaRecruiting

MetastasisRecruiting

Brain InjuryRecruiting

GlioblastomaActive, not recruiting

Prostate CancerPhase 2

Terminated

Pancreatic CancerPreclinical

Active, not recruiting

Pulmonary Arterial HypertensionPreclinical

Active, not recruiting

ImagingPhase 2

Recruiting

ImmunotherapyPhase 2

Not yet recruiting

Neuroendocrine TumorsPhase 2

Recruiting

GliomaPhase 1

Recruiting

MetastasisPhase 1

Recruiting

Brain InjuryPhase 1

Recruiting

GlioblastomaPhase 1

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

25 2

Verzenio

Eli Lilly

Phase 3

5 3

Provenge

PProstate Oncology Specialists, Inc.

Phase 3

21 4

Aglatimagene Besadenovec

CCandel Therapeutics, Inc.

Phase 3

2 5

AAA817

Novartis

Phase 3

1 6

Hyperpolarized 13C Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

2 7

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 8

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Prostate Cancer

NCT02526368

Recruiting

Brain Tumors

NCT03067467

Q1 2027

Phase 1Recruiting

Metastasis

NCT03324360

Q4 2027

Phase 1Recruiting

Brain Injury

NCT06103201

Phase 1Recruiting

Glioma

NCT04772456

Q1 2028

Phase 2Recruiting

Neuroendocrine Tumors

NCT05746208

Clinical

Trials by Indication[1]

Cervical Cancer2 trials

Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy

Completed·—·Phase 2·NCT04951921·6 enrolled

Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

Terminated·SSunnybrook Health Sciences Centre·Phase 1·NCT03129776·4 enrolled

Prostate Cancer2 trials

Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer

Recruiting·IIvan de Kouchkovsky, MD·Phase 1·NCT02526368·80 enrolled

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging in the Diagnosis and Risk-Stratification of Prostate Cancer

Terminated·UUniversity of Maryland, Baltimore·Phase 2·NCT04698564·4 enrolled

Glioma1 trial

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT04772456·5 enrolled

Glioblastoma1 trial

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

Active, not recruiting·SSusan Chang·Phase 1·NCT04019002·17 enrolled

Brain Injury1 trial

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT06103201·15 enrolled

10 more indications

Imaging1 trial

Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

Recruiting·NNational Heart Centre Singapore·Phase 2·NCT06645691·200 enrolled

Magnetic Resonance Imaging1 trial

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

Enrolling by invitation·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05041166·50 enrolled

Metastasis1 trial

Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)

Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT03324360·276 enrolled

Pulmonary Arterial Hypertension1 trial

Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

Completed·UUniversity of Texas Southwestern Medical Center··NCT04968210·3 enrolled

Neuroendocrine Tumors1 trial

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT05746208·29 enrolled

Immunotherapy1 trial

Hyperpolarized 13C MRI for Cancer Immunotherapy

Not yet recruiting·—·Phase 2·NCT05805358·90 enrolled

Cancers1 trial

HP Pyruvate MRI in Cancers

Recruiting·UUniversity of Maryland, Baltimore·Phase 1/2·NCT05697406·25 enrolled

Pancreatic Cancer1 trial

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Recruiting·UUniversity of California, San Francisco··NCT06600906·70 enrolled

Advanced Solid Tumors1 trial

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Recruiting·RRobert Bok, MD, PhD·Phase 1/2·NCT05599048·65 enrolled

Brain Tumors1 trial

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Recruiting·UUniversity of Texas Southwestern Medical Center··NCT03067467·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Hyperpolarized 13C Pyruvate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized 13C Pyruvate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized 13C Pyruvate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Maryland, Baltimore

Hyperpolarized 13C Pyruvate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Cervical Cancer2 trials

Prostate Cancer2 trials

Glioma1 trial

Glioblastoma1 trial

Brain Injury1 trial

Imaging1 trial

Magnetic Resonance Imaging1 trial

Metastasis1 trial

Pulmonary Arterial Hypertension1 trial

Neuroendocrine Tumors1 trial

Immunotherapy1 trial

Cancers1 trial

Pancreatic Cancer1 trial

Advanced Solid Tumors1 trial

Brain Tumors1 trial

References

Drug Info

Quick Facts

Related News